Speech highlights the need for inhalation-based prescription nicotine replacement therapy to address efficacy shortfalls of current treatment options RICHMOND, Va. , Oct. 21, 2024 /PRNewswire/ -- Qnovia, Inc.
announced its CEO is speaking publicly to FDA and NIH at the joint agency public meeting on Advancing Smoking Cessation today at FDA's White Oak Campus. Qnovia is a pharmaceutical company that recently announced the clearance of its Investigational New Drug (IND) application by FDA for the RespiRxTM Nicotine Inhaler (QN-01), a prescription inhaled smoking cessation medicine. "I am encouraged by the opportunities recently outlined by FDA and NIH for pursuing innovation in smoking cessation, an area with no new therapies approved in several decades.
A modernization of the approach to smoking cessation medicines is overdue, and I am hopeful today's discussion will lead to more innovation in the industry," stated Brian Quigley , Chief Executive Officer of Qnovia. "The currently available nicotine replacement therapies (NRTs) deliver nicotine buccally or transdermally, resulting in suboptimal nicotine concentrations and ultimately a failure to provide relief from cravings or withdrawals in the real world. We believe an NRT that safely delivers pharmaceutical grade nicotine using the pulmonary route of administration can address the shortcomings of existing therapies.
We are committed to directly addressing this unmet public health need through the development of our lead asse.